Publications
2024
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.
Liew, F., Efstathiou, C., Fontanella, S., Richardson, M., Saunders, R., Swieboda, D., . . . ISARIC investigators. (2024). Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.. Nature immunology, 25(4), 607-621. doi:10.1038/s41590-024-01778-0
2023
Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.
Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., . . . ISARIC4C investigators. (2023). Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.. The Journal of infectious diseases, jiad590. doi:10.1093/infdis/jiad590
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2023). Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 14(1), 8487. doi:10.1038/s41467-023-42320-4
International Pediatric COVID-19 Severity Over the Course of the Pandemic
Zhu, Y., Almeida, F. J., Baillie, J. K., Bowen, A. C., Britton, P. N., Brizuela, M. E., . . . Short, K. R. (2023). International Pediatric COVID-19 Severity Over the Course of the Pandemic. JAMA PEDIATRICS. doi:10.1001/jamapediatrics.2023.3117
A second update on mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative. (2023). A second update on mapping the human genetic architecture of COVID-19.. Nature, 621(7977), E7-E26. doi:10.1038/s41586-023-06355-3
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402